In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
The effect of heart rate on brachial and central blood pressure in longterm beta-blocker therapy
2018

Congress : ESC Congress

  • Topic : hypertension
  • Sub-topic : Hypertension: Pharmacotherapy
  • Session type : Poster Session
  • FP Number : P3807

Authors : M Serg (Tartu,EE), T Teeaar (Tartu,EE), J Eha (Tartu,EE), M Zilmer (Tartu,EE), J Kals (Tartu,EE), P Kampus (Tartu,EE)

15 views

Authors:
M. Serg1 , T. Teeaar1 , J. Eha1 , M. Zilmer2 , J. Kals2 , P. Kampus1 , 1University of Tartu, Department of Cardiology, Institute of Clinical Medicine - Tartu - Estonia , 2University of Tartu, Department of Biochemistry, Institute of Biomedicine and Translational Medicine - Tartu - Estonia ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 808

Background: Increased resting heart rate (HR) contributes to higher cardiovascular risk. We have previously shown that a conventional beta-blocker (BB) metoprolol and a vasodilating BB nebivolol equally reduce brachial blood pressure (BP) and HR, only nebivolol reduces central (aortic) BP. However, recent short-term studies have proposed that baseline HR values as well as change in HR with BB may augment central BP. Therefore, the use of BBs as antihypertensive drugs remains controversial.

Purpose: We aimed to study whether baseline HR level determines the change in brachial and central BP in long-term BB therapy in hypertensive patients.

Methods: We conducted a randomized, double-blind study in 80 hypertensive patients, who received either nebivolol 5 mg or metoprolol succinate 50–100 mg daily for one year. We performed brachial and central BP measurements at baseline and at the end of the study. The patients in each treatment arm were then divided into subgroups by their baseline HR (<65 bpm and ≥65 bpm).

Results: After 1 year of treatment brachial BP was reduced in all subgroups. In patients with baseline HR <65 bpm there was no change in HR and central BP in the metoprolol group, whereas in these patients nebivolol significantly reduced HR and central systolic BP (130±15 vs. 120±14 mmHg; p<0.01) and pulse pressure (49±10 vs. 43±8 mmHg; p=0.01). In patients with baseline HR ≥65 bpm both, metoprolol and nebivolol reduced HR significantly, but there was a significant reduction in central systolic BP (136±17 vs. 125±11 mmHg; p<0.05) only in the nebivolol group.

Conclusion: Our study suggests that despite HR and brachial BP reduction with BBs there is no additional augmentation of central BP. Vasodilating BB nebivolol reduces brachial and central BP regardless of baseline HR level.

Please login to My ESC

This content may be restricted, please sign in to check your access.

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are